Lymphedema as an initial manifestation of paraneoplastic rheumatic syndromes: a case series of six patients

Objective Lymphedema as the initial symptom poses significant challenges in the early diagnosis of underlying malignancies masquerading as rheumatic diseases. Methods This study retrospectively analyzed six patients who were hospitalized at Beijing Shijitan Hospital between October 2015 and October 2025 with paraneoplastic rheumatic syndromes (PRS) presenting with lymphedema as the initial manifestation. Data on clinical manifestation, laboratory and imaging findings, diagnoses, treatments, and prognosis were collected. Results Six patients (3 males, 3 females; median age 66 years) presented with lymphedema as the initial manifestation of PRS. The initial rheumatologic diagnoses were leukocytoclastic vasculitis (n=2), undifferentiated connective tissue disease (n=2), Sjögren’s syndrome (n=1), and anti-synthetase syndrome (n=1). The median interval from lymphedema onset to rheumatic diagnosis was 5.5 months. All patients received glucocorticoids, and four received immunosuppressants; none achieved durable benefit. The median interval from rheumatic diagnosis to therapy failure was 1 month, and from therapy failure to cancer diagnosis was 1 month. The underlying malignancies included lymphoma (n=3), lung adenocarcinoma (n=2), and gastric adenocarcinoma (n=1). During a follow-up of 1 to 13 months, two patients showed significant improvement in lymphedema, whereas the remaining four died. Conclusion Malignancies may present with lymphedema as the initial symptom, mimicking rheumatic diseases. Underlying malignancy should be highly suspected, particularly when there is a poor response to immunosuppressive therapy. Early recognition and screening for malignancies are crucial for improving patient outcomes.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-10-26
DOI
https://doi.org/10.3389/fonc.2026.1964817
Primary Topic
Autoimmune Neurological Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lymphedema as an initial manifestation of paraneoplastic rheumatic syndromes: a case series of six patients

Weixia Wang, Min-Na Jiang, Yuhua Wang, Guohua Zhang et al.
Frontiers in Oncology
Autoimmune Neurological Disorders and Treatments
article

Lymphedema as an initial manifestation of paraneoplastic rheumatic syndromes: a case series of six patients

Weixia Wang, Min-Na Jiang, Yuhua Wang, Guohua Zhang, Kai-Li Zhong, Ling-Ling Zhang
article en

Abstract

Objective Lymphedema as the initial symptom poses significant challenges in the early diagnosis of underlying malignancies masquerading as rheumatic diseases. Methods This study retrospectively analyzed six patients who were hospitalized at Beijing Shijitan Hospital between October 2015 and October 2025 with paraneoplastic rheumatic syndromes (PRS) presenting with lymphedema as the initial manifestation. Data on clinical manifestation, laboratory and imaging findings, diagnoses, treatments, and prognosis were collected. Results Six patients (3 males, 3 females; median age 66 years) presented with lymphedema as the initial manifestation of PRS. The initial rheumatologic diagnoses were leukocytoclastic vasculitis (n=2), undifferentiated connective tissue disease (n=2), Sjögren’s syndrome (n=1), and anti-synthetase syndrome (n=1). The median interval from lymphedema onset to rheumatic diagnosis was 5.5 months. All patients received glucocorticoids, and four received immunosuppressants; none achieved durable benefit. The median interval from rheumatic diagnosis to therapy failure was 1 month, and from therapy failure to cancer diagnosis was 1 month. The underlying malignancies included lymphoma (n=3), lung adenocarcinoma (n=2), and gastric adenocarcinoma (n=1). During a follow-up of 1 to 13 months, two patients showed significant improvement in lymphedema, whereas the remaining four died. Conclusion Malignancies may present with lymphedema as the initial symptom, mimicking rheumatic diseases. Underlying malignancy should be highly suspected, particularly when there is a poor response to immunosuppressive therapy. Early recognition and screening for malignancies are crucial for improving patient outcomes.

Frontiers in OncologyVol. 16
Capital Medical University (CN), Beijing Shijitan Hospital (CN)
Openalex Percentile: Top 14%
Autoimmune Neurological Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon